Highly ExpandableCord Blood ECFCs
What are ECFCs?
Endothelial Colony Forming Cells (ECFCs) are rare, highly proliferative, circulating endothelial progenitor cells capable of regenerating blood vessels and repairing damaged vascular endothelial linings. Clonally isolated from cord blood, a single ECFC can give rise to a homogeneous, highly expandable population of bona fide endothelial cells capable of forming functional blood vessels.
Detailed comparisons: how CB-ECFCs differ from HUVEC, HAEC, HMVEC, and iPSC-derived endothelial cells.
What can ECFCs do?
CB-ECFCs are backed by decades of peer-reviewed research, with thousands of studies spanning vascular repair, disease modeling, and regenerative medicine. Researchers use our cells for angiogenesis assays, drug screening, vascularized organoid co-cultures, and in vivo vessel formation studies — a homogeneous, highly expandable alternative to HUVEC, HAEC, HMVEC, and iPSC-derived endothelial cells. Browse by research workflow or disease area.
Common questions
How CB-ECFCs compare to HUVEC, HAEC, HMVEC, and iPSC-derived endothelial cells — and what to expect from our cells in your assays.
CB-ECFCs (Cord Blood-derived Endothelial Colony Forming Cells) are rare, highly proliferative endothelial progenitor cells isolated from human cord blood. They are bona fide endothelial cells capable of forming functional blood vessels, making them ideal for vascular biology research, angiogenesis studies, drug screening, and regenerative medicine applications.
HUVECs (Human Umbilical Vein Endothelial Cells) are pooled, en masse from adult umbilical vein tissue, producing a heterogeneous mixture of donor cells with limited expansion capacity that senesces within a few passages. CB-ECFCs are clonally isolated from a single cord blood progenitor — yielding a homogeneous population with extensive proliferative capacity, high lot-to-lot reproducibility, and the ability to form durable, perfused vessels in vivo. ECFCs are considered the true endothelial stem/progenitor cell, whereas HUVECs are mature, terminally differentiated endothelial cells.
Yes. iPSC-derived endothelial cells (iPSC-ECs) offer homogeneity but often fail to fully recapitulate the functions of primary endothelial cells, particularly in vivo vessel formation, sprouting angiogenesis, and barrier function. CB-ECFCs are primary cells with native endothelial function, while still being homogeneous due to their clonal origin — combining the consistency of iPSC-ECs with the authentic biology of primary cells.
Yes. CB-ECFCs perform robustly in standard endothelial assays including Matrigel tube formation, sprouting angiogenesis, transwell migration, shear stress / flow chamber experiments, co-culture with pericytes or stromal cells, vascularized organoid and organ-on-chip systems, and in vivo vasculogenesis (e.g., subcutaneous Matrigel plug). Their extensive expansion capacity enables larger experiments and cell-intensive assays that quickly exhaust HUVEC stocks.
HAEC (Human Aortic Endothelial Cells), HMVEC (Human Microvascular Endothelial Cells), and similar adult-tissue-derived primary endothelial cells share HUVEC's main limitations: heterogeneity from pooled donors, donor-age-related variability, and limited expansion before senescence. CB-ECFCs offer neonatal-origin biology (younger cells, longer telomeres), clonal homogeneity, and an order-of-magnitude greater expansion capacity, making them better suited for long-term studies, large-scale screens, and reproducible multi-experiment workflows.
ClonalStem CB-ECFCs are >95% pure with positive expression of endothelial markers CD31 and CD144 (VE-Cadherin) and Neuropilin-1 (NRP1), and are negative for the leukocyte marker CD45. Viability is >90%, with a population doubling time of approximately 27 hours.
CB-ECFCs are versatile primary endothelial cells suitable for vascular biology research, angiogenesis and vasculogenesis studies, drug screening, regenerative medicine, vascularized organoid generation, organ-on-chip vasculature, tumor microenvironment modeling, blood-brain barrier modeling, sprouting assays, shear-stress experiments, and in vivo vessel formation studies.
Research
Beyond our catalog, ClonalStem maintains an active R&D portfolio exploring the translational potential of cord blood-derived endothelial progenitors. Partner with us!
Leadership
Serial founders and translational experts bridging vascular biology, advanced science, and scalable therapeutic development.
Serial entrepreneur translating breakthrough science into clinical-stage cell therapies. Over the last decade he has advanced multiple cellular medicine ventures, several now in clinical development. Committed to disease-modifying and curative medicines for serious conditions.
Translational scientist and biotech entrepreneur with a scientific background spanning small-molecule drug screening to IND-enabling cell and gene therapy, including a successful FDA pre-IND. He also brings expertise in venture creation, commercialization, operations, and investments. Committed to translating breakthrough biology into scalable therapies that improve patient quality of life.